U.S. Capital Wealth Advisors’s Royalty Pharma RPRX Stock Holding History

U.S. Capital Wealth Advisors’s Portfolio RPRX Stock Details RPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-16,079	Closed	-$646K	–	1616
2022 Q3	$646K	Hold	16,079	–	–	0.03%	402
2022 Q2	$676K	Hold	16,079	–	–	0.03%	412
2022 Q1	$626K	Hold	16,079	–	–	0.02%	469
2021 Q4	$641K	Sell	16,079 -4,170	-21%	-$162K	0.03%	472
2021 Q3	$794K	Buy	+20,249	New	+$787K	0.03%	430

Other funds holding RPRX

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

U.S. Capital Wealth Advisors's RPRX Position: Q4 2022 in Review

U.S. Capital Wealth Advisors sold out of Royalty Pharma (RPRX) in Q4 2022, closing a stake of 16,079 shares — an estimated $646K sold.

U.S. Capital Wealth Advisors first reported a position in RPRX in Q3 2021 and held it in 5 quarters. The position peaked at $794K in Q3 2021. 334 funds tracked by Wall St. Rank hold RPRX as of Q4 2022.

U.S. Capital Wealth Advisors reported no remaining Royalty Pharma position as of Q4 2022 after selling out during the quarter.
U.S. Capital Wealth Advisors sold 16,079 Royalty Pharma shares in Q4 2022, an estimated $646K.
U.S. Capital Wealth Advisors first reported a position in Royalty Pharma in Q3 2021 and held it in 5 quarters.
U.S. Capital Wealth Advisors's Royalty Pharma position peaked at $794K in Q3 2021.
334 funds tracked by Wall St. Rank held Royalty Pharma as of Q4 2022.

Based on U.S. Capital Wealth Advisors's 13F filing for Q4 2022, filed 3 Feb 2023.